All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

New heterocyclic compounds with strong CDK inhibitory and anticancer properties.

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F04%3A00002120" target="_blank" >RIV/61989592:15310/04:00002120 - isvavai.cz</a>

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    New heterocyclic compounds with strong CDK inhibitory and anticancer properties.

  • Original language description

    Recently, a deregulation of cyclin-dependent kinases (CDKs) has been proved in human primary tumors and in tumor cell lines. The discovery evoked a strong interest in inhibitors of CDKs that could play a role in the therapy of cancers. Series of 2-, 6-,8-, 9-tetrasubstituted purines, 3-, 7-disubstituted pyrazolo 4,3-d pyrimidines, and 2-, 6-, 9-trisubstituted 1,2,3-triazolo 4,5-d pyrimidines (8-azapurines), which specifically inhibits some CDKs at micromolar concentrations have been developed.. The compounds display (1) an enhanced inhibitory activity toward CDK1/2, or (2) a higher selectivity for some CDKs, or (3) an increased antimitotic activity at the G1/S and G2/M points of the cell cycle, and finally (4) stronger and more selective antitumor effects. Hence they can be used as antimitotic drugs, in particular, in chemotherapy of cancer, therapy of psoriasis and parasitoses as those caused by fungi or protists, treatment of Alzheimer´s disease or as antineurodegenerative drugs.

  • Czech name

    Nové heterocyklické sloučeniny se silnými CDK-inhibičními a protinádorovými vlastnostmi.

  • Czech description

    Deregulace cyklin-dependentních (CDK) kinas úzce souvisí se vznikem růstem nádorů. Tato skutečnost vyvolala zájem o specifické inhibitory CDK použitelné v terapii nádorových onemocnění. Vyvinuli jsme série specifických inhibitorů CDK na bázi 2,6,8,9-tetrasubstituovaných purinů, 3,7-disubstituovaných pyrazolo[4,3-d]pyrimidinů a 2,6,9-trisubstituovaných 1,2,3-triazolo[4,5-d]pyrimidinů (8-azapurinů). Tyto sloučeniny vykazují silnou inhibiční aktivitu na CDK1/2, vyšší selektivitu pro CDK, silnou antimitotickou aktivitu a pozoruhodné protinádorové účinky. Mohou proto být použity jako antimitotické látky, zvláště pak jako protinádorová chemoterapeutika, léčiva pro prosiasu, parasitosy, Alzeimerovy choroby a jiných antineurodegenerativních poruch.

Classification

  • Type

    D - Article in proceedings

  • CEP classification

    ED - Physiology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    Z - Vyzkumny zamer (s odkazem do CEZ)

Others

  • Publication year

    2004

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Article name in the collection

    Cell Cycle and Cancer: Pathways and Therapies

  • ISBN

  • ISSN

  • e-ISSN

  • Number of pages

    225

  • Pages from-to

    "B6"

  • Publisher name

    American Association for Cancer Research

  • Place of publication

    Florida

  • Event location

  • Event date

  • Type of event by nationality

  • UT code for WoS article